Literature DB >> 26280465

Incomplete erythropoietic protoporphyria caused by a splice site modulator homozygous IVS3-48C polymorphism in the ferrochelatase gene.

M Mizawa1, T Makino1, H Nakano2, D Sawamura2, T Shimizu1.   

Abstract

Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria caused by both the partial deficiency of ferrochelatase (FECH) and the existence of cytosine at IVS3-48 in trans to a mutated FECH allele. However, physicians occasionally encounter patients with EPP with a mild phenotype associated with a slight increase in the erythrocyte-free protoporphyrin concentration and no FECH gene mutations. In this study, genetic analyses were performed on three patients with a mild phenotype of EPP, with photosensitivity, slightly increased erythrocyte-free protoporphyrin concentrations and only a few fluorocytes in the peripheral blood. After obtaining the patients' and their parents' informed consent, a direct sequence analysis of the FECH gene and a restriction fragment length polymorphism analysis were performed on samples from the patients. The FECH gene mutation was not detected in the direct sequence analyses in any of the patients. However, all three patients had the homozygous IVS3-48C polymorphism. These findings suggest that homozygous IVS3-48C polymorphism of the FECH gene is associated with a slight elevation of the protoporphyrin level in erythrocytes, resulting in a mild EPP phenotype.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26280465     DOI: 10.1111/bjd.14078

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database.

Authors:  Pei Li; Dhiman Maitra; Ning Kuo; Herbert L Bonkovsky; M Bishr Omary
Journal:  Blood Adv       Date:  2021-01-12

Review 2.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

3.  Cimetidine/lactulose therapy ameliorates erythropoietic protoporphyria-related liver injury.

Authors:  Naoyuki Fujimori; Michiharu Komatsu; Naoki Tanaka; Mai Iwaya; Hajime Nakano; Ayumi Sugiura; Tomoo Yamazaki; Soichiro Shibata; Yugo Iwaya; Takashi Muraki; Yuki Ichikawa; Takefumi Kimura; Satoru Joshita; Takeji Umemura; Akihiro Matsumoto; Eiji Tanaka
Journal:  Clin J Gastroenterol       Date:  2017-07-04

4.  The 6-year follow-up of a Japanese patient with silent erythropoietic protoporphyria.

Authors:  Megumi Mizawa; Teruhiko Makino; Fumina Furukawa; Ryotaro Torai; Hajime Nakano; Daisuke Sawamura; Tadamichi Shimizu
Journal:  JAAD Case Rep       Date:  2017-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.